PCYT2 and colorectal carcinoma: This possibility is supported by the results of IHC staining in 40 CRC patient tissues, which indicated that patients with CRC with expression of PCYT2 (n = 21) had shorter progression-free survival (PFS) times, whereas patients with high PCYT2 expression (n = 19) had longer PFS times (Figure 1H).